Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Shionogi Notches Double-Digit Sales Rise on HIV/Flu Royalties
Shionogi racked up a double-digit increase in its half-year revenue through September, as a buoyant royalty income more than offset a dip in its ethical drug business in Japan, with its profits on all levels reaching all-time highs, the company…
To read the full story
Related Article
- Shionogi’s Net Profit Crosses 100 Billion Yen Mark in FY2017
May 10, 2018
- Global Sales of Shionogi’s Novel Influenza Drug Could Reach US$1 Billion: President
November 1, 2017
- Shionogi Ups Earnings Outlook on Milestone Scheme Change
October 24, 2017
- Shionogi Enjoys Rise in Japan Sales, Profits on HIV Royalty Revenue
May 11, 2017
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…